Evidence map›Paper›PMID 42568601›Full record

ArticleFrontiers in cellular and infection microbiology2026

Host inflammatory markers and MLVA profiling for risk assessment of severe pediatric

Huan Xu, Jingmin Zhang, Shujuan Jiang, Jingxuan Xu, Xiaoqian Huang, Shuning Sun, Han Yan, Zhaoyong Lv, Daogang Qin, Jing Wang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Huan XuKey Laboratory for Pediatrics of Integrated Traditional and Western Medicine, Liaocheng People's Hospital, Liaocheng, Shandong, China.
Jingmin ZhangKey Laboratory for Pediatrics of Integrated Traditional and Western Medicine, Liaocheng People's Hospital, Liaocheng, Shandong, China.
Shujuan JiangDepartment of Pediatrics, Liaocheng People's Hospital, Liaocheng, Shandong, China.
Jingxuan XuKey Laboratory for Pediatrics of Integrated Traditional and Western Medicine, Liaocheng People's Hospital, Liaocheng, Shandong, China.
Xiaoqian HuangKey Laboratory for Pediatrics of Integrated Traditional and Western Medicine, Liaocheng People's Hospital, Liaocheng, Shandong, China.
Shuning SunKey Laboratory for Pediatrics of Integrated Traditional and Western Medicine, Liaocheng People's Hospital, Liaocheng, Shandong, China.
Han YanKey Laboratory for Pediatrics of Integrated Traditional and Western Medicine, Liaocheng People's Hospital, Liaocheng, Shandong, China.
Zhaoyong LvKey Laboratory for Pediatrics of Integrated Traditional and Western Medicine, Liaocheng People's Hospital, Liaocheng, Shandong, China.
Daogang QinDepartment of Pediatrics, Liaocheng People's Hospital, Liaocheng, Shandong, China.
Jing WangKey Laboratory for Pediatrics of Integrated Traditional and Western Medicine, Liaocheng People's Hospital, Liaocheng, Shandong, China.
Ting WangKey Laboratory for Pediatrics of Integrated Traditional and Western Medicine, Liaocheng People's Hospital, Liaocheng, Shandong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Methods: We retrospectively enrolled 421 children hospitalized with MP pneumonia (MPP) between January 2023 and December 2024 in this study. Clinical and laboratory data were collected. Results: Of the 421 patients, 212 (50.4%) were diagnosed with SMPP. Children with SMPP were significantly older than those with general MPP (GMPP) ( Conclusion: This study reveals a high rate of macrolide-resistant MP in Liaocheng, largely caused by the A2063G mutation. Elevated D-dimer and elevated LDH are independent predictors of SMPP. Certain MLVA subtypes are significantly associated with disease severity, suggesting they may help in risk assessment and clinical decision-making.

Indexed as

Mycoplasma pneumoniaePneumonia, MycoplasmaAnti-Bacterial AgentsBiomarkersChildChild, PreschoolChinaCommunity-Acquired PneumoniaDrug Resistance, BacterialFemaleHumansInfantMacrolidesMaleMinisatellite RepeatsMultilocus Sequence TypingAnti-Bacterial AgentsBiomarkersMacrolidesRNA, Ribosomal, 23Schildrenmacrolide resistancemultilocus variable-number tandem repeat analysis (MLVA)Mycoplasma pneumoniae (MP)severe Mycoplasma pneumoniae pneumonia (SMPP)

Identifiers

PMID42568601
PMCPMC13447276

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.